Emergent BioSolutions Secures $64.5M U.S. Contract for BAT® Antitoxin
GAITHERSBURG, Md. | May 28, 2026 Emergent BioSolutions announced it has received a $64.5 million contract modification from the...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
GAITHERSBURG, Md. | May 28, 2026 Emergent BioSolutions announced it has received a $64.5 million contract modification from the...
COPENHAGEN, DENMARK — February 18, 2026 Bavarian Nordic has secured a USD 22.5 million vaccine supply contract from the...
JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...
